A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma

A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma

Authors

  • Ayşe Akbaş Ankara City Hospital, Dermatology, Ankara, Turkey
  • Fadime Kılınç Ankara City Hospital, Dermatology, Ankara, Turkey
  • Yıldız Hayran Ankara City Hospital, Dermatology, Ankara, Turkey

Keywords:

Adult, child, epidemiology, localized scleroderma, morphea

Abstract

Introduction: Morphea localized scleroderma (LS) is a rare skin disease with unknown pathogenesis, which causes sclerosis of the dermis and subcutaneous tissue.

Objectives: It was aimed to compare the characteristics of patients with pediatric and adult-onset morphea.

Methods: A retrospective analysis was performed on the records of 183 adult morphea patients. The demographics, clinical and laboratory characteristics, and treatment options of the patients were recorded. Adult patients with morphea over the age of 18 were divided into two groups according to the age of onset and compared.

Results: Twenty-two percent (N = 41) of the patients had pediatric-onset morphea (POLS) and 77.6% (n=142) had adult-onset morphea (AOLS). While POLS had a higher head-neck involvement, AOLS had a higher breast involvement (P < 0.001 and P = 0.043). Patients with linear morphea were younger, and more frequently had at least one laboratory anomaly (P = 0.016 versus 0.024). Anti-dsDNA positivity and low hemoglobin (Hb) were observed more frequently in patients with breast involvement. Patients with inguinal involvement, on the other hand, had lower Hb and a higher rate of diabetes, and those patients were older (P = 0.042, 0.040, and 0.012, respectively).

Conclusions: Clinical characteristics and accompanying laboratory anomalies of the patients with morphea depend on the age of onset, involvement areas and the types of morphea, having such data readily available should guide the holistic approach for, and the monitoring process of, the disease.

References

REFERENCES

Abbas L, Joseph A, Kunzler E, Jacobe HT. Morphea: progress to date and the road ahead. Ann Transl Med.2021;9(5):437. DOI: 10.21037/atm-20-6222. PMID: 33842658; PMCID: PMC8033330.

Fett N,Werth VP.Update on morphea: part I. epidemiology, clinical presentation, and

pathogenesis. J Am Acad Dermatol. 2011;64( 2)):217-28; quiz 229-30.PMID.21238823;

DOI:10.1016/j.jaad.2010.05.045

Khamaganova I. Localized scleroderma predisposing and trigerring factors. The Open Dermatology Journal.2017;1:11.DOI:10.2174/1874372201711010001.

Bielsa Marsol I. Update on the classification and treatmentof localized scleroderma. Actas Dermosifiliogr. 2013;104(8):654-66.PMID 23948159;DOI10.1016/j.adengl.2012.

Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24(1):73-80. PMID: 9002014.

Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545-50. DOI: 10.1001/archdermatol.2009.79. PMID: 19451498; PMCID: PMC2938024.

Careta MF, Romiti R. Localized scleroderma: clinical spectrumand therapeutic update. An Bras Dermatol.2015; 90(1):62-73.PMID: 25672301; DOI:10.1590/abd1806-4841.20152890.

Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol.2006;18(6):606-13. PMID: 17053506; DOI:10.1097/01.bor.000245727.40630.c3.

Bulur I, Erdoğan HK, Karapınar T, Saracoglu ZN. Morphea in Middle Anatolia, Turkey: a 5-year single-center experience.Postepy Allegol.2017;34(4):334-8.PMID:28951708;DOI.org/10.51114/ada.2017.69313.

Parlak N, Akay BN, Şanlı HE, Akyol A. Hastalarda klinik özellikler,laboratuvar bulguları,seçilen tedavi yöntemi ve takip sonuçları [The clinical features, laboratoryfindings, treatment and follow-up results of patients with morphea]. Turkderm. 2013;47(4):209-13.DOI.104274/turkderm.05657.

Condie D, Grabell D, Jacobe H. Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort. Arthritis Rheumatol. 2014;66(12):3496-504. DOI: 10.1002/art.38853. PMID: 25156342; PMCID: PMC4245331.

Alhumidi A, Alanazi SM, Alfaraidi M,Alshamlan N,Alanazi A,Khalil R et al.Morphea in Saudi Arabia, a clinical study of 64 patients. 2017;Clin Res Dermatol Open Access. 4(4): 1-7. DOI: http://dx.DOI.org/10.15226/2378-1726/4/4/00167.

Zulian F, Athreya BH, Laxer R, Nelson AM. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology(Oxford). 2006;45(5):614-20.PMID: 16368732;DOI:10.1093/rheumatology/kei251.

Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC,et al. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease.Br J Dermatol. 2015;172(3):722-8. DOI: 10.1111/bjd.13514. Epub 2015 Feb 8. PMID: 25381928.

Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13(2):171-6. PMID: 12695134.

Wu EY, Li SC, Torok KS,Viekud Y, Fuhlbrigge R,Rabinovich E et al. Description of the juvenile localized scleroderma subgroup of the CARRA Registry. Arthritis Rheumatol (Hoboken, NJ).2014; 66(Suppl 11):S43–4.DOI10.1002/art.38444.

Akbas A, Kılınç F. Clinical and demographic characteristics of pediatric patients diagnosed with localized scleroderma: A retrospective analysis. Türkiye Çocuk Hastalıkları Dergisi. 2022; 16.1: 25-31.

Saracino AM, George C, Nihtyanova SI, Denton CP. Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centre. J Scleroderma Relat Disord. 2021 ;6(1):102-108. DOI: 10.1177/2397198320925684. Epub 2020 Jun 12. PMID: 35382251; PMCID: PMC8922636.

Kim J, Chung KB, Lee YI, Kim J, Lee JH. Clinical characteristics and histopathologic changes of morphea: A single-center, retrospective study of 137 patients. J Am Acad Dermatol. 2021 ;85(1):105-113. DOI: 10.1016/j.jaad.2020.11.006. Epub 2020 Nov 12. PMID: 33188871.

Lis-Święty A, Skrzypek-Salamon A, Ranosz-Janicka I, Brzezińska-Wcisło L.Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. J Eur Acad DermatolVenereol. 2017;31(10):1595-603. PMID: 28271552.;DOI: 10.1111/jdv.14197.

Kunzler E, Florez-Pollack S, Teske N, O’Brien J, Prasad S, Jacobe H. Linear morphea: clinical characteristics, disease course, and treatment of the morphea in adults and children cohort.J Am Acad Dermatol. 2019;80(6):1664-1670.e1. DOI:10. 1016/j.jaad.2019.01.050

D'Amico E, Zanghì A, Romano A, Sciandra M, Palumbo GAM, Patti F. The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells. 2019 Sep 20;8(10):1114. DOI: 10.3390/cells8101114. PMID: 31547008; PMCID: PMC6830321..

Arif T, Adil M, Amin SS, Tahseen M, Dorjay K, Mohtashim M, et al. D. Clinico-epidemiological study of morphea from a tertiary care hospital. Curr Rheumatol Rev. 2018;14(3):251-254. DOI: 10.2174/1573397114666180410115553. PMID: 29637865.

Weber K.Is juvenile localized scleroderma related to Lyme borreliozis? J Am Acad Dermatol. 2009; 61(5):901. PMID:19836648;DOI:10.1016/j.jaad.2009.05.022. DOI: 10.1093/rheumatology/ker142. Epub 2011 Jul 5. PubMed PMID: 21729934.

Zulian F ,Vallongo C, Woo P, Russo R, Ruperto N, Harper J et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005 ;52(9):2873-81. PMID:16142730.

Saxton-Daniels S, Jacobe HT. An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010; 146(9):1044–5. DOI: 10.1001/archdermatol.2010.239. PMID: 20855712; PMCID: PMC2945300.

Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: current concepts. Clin Dermatol. 2018;36:475–86. DOI: 10.1016/j.clindermatol.2018.04.005. Epub 2018 Apr 10. PMID: 30047431.

Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986;104(6):849-57. DOI: 10.7326/0003-4819-104-6-849. PMID: 3486617

Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol. 1994;31(4):567-71.PMID: 8089281.

Arkachaisri T, Fertig N, Pino S, Medsger TA. Serum autoantibodies and their clinical associations in patients with childhood‑ and adult‑onset linear scleroderma. A single‑center study. J Rheumatol. 2008;35:2439‑44.

Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in Morphea: An Update. Front Immunol. 2019 (9);10:1487. DOI: 10.3389/fimmu.2019.01487. PMID: 31354701; PMCID: PMC6634257.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatology Venereol. 2017;31:1401-1424

Woo TY ,Rasmussen JE.Juvenile linear scleroderma associated with serologic abnormalities Arch Dermatol. 1985;121(11):1403-5. PMID: 3876808

Dharamsi JW, Victor S, Aguwa N, Ahn C, Arnett F, Mayes MD, et al. Morphea in adults and children cohort III: Nested case-control study: the clinical significance of autoantibodies in morphea. JAMA Dermatol. 2013; 149(10):1159–65. DOI: 10.1001/jamadermatol.2013.4207. PMID: 23925398; PMCID: PMC4153681.

Alimova E,Farhi D,Plantier F,et al.Morphea (localizedscleroderma):Baseline body surface

involvement and antinuclear antibody may have a prognostic value. Clin Exp Dermatol.2009;34(7):e491-2.PMID:19747327;DOI:10.1111/j.1365-2230.2009.03557.x.

Fett N, Werth VP. Update on morphea: part II. Outcome measuresand treatment. J Am Acad Dermatol. 2011; 64(2): 231-42. quiz 243-4.PMID:-21238824;DOI:10.1016/j.jaad.2010.05.046

Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M,et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol.2012;67(6):1151-6. DOI: 10.1016/j.jaad.2012.03.036. Epub 2012 May 30. PMID: 22657157.

Litaiem N, Bacha T, Drissi H, Zeglaoui F. An evaluation of long-term outcomes and recurrence rates in patients with morphea. Int J Dermatol. 2019 ;58(4):E90-E92. DOI: 10.1111/ijd.14401. Epub 2019 Feb 1. PMID: 30710337.

El-Sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF.The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol .1999;161(6):1980-3.PMID: 10332485.

Noh JW, Kim J, Kim JW. Localized scleroderma: a clinical study at a single

center in Korea. Int J Rheum Dis. 2013;16(4):437-41. PMID: 23992265;DOI:10.1111/1756-185X.12080.

Downloads

Published

2024-01-31

Issue

Section

Original Article

How to Cite

1.
A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma. Dermatol Pract Concept [Internet]. 2024 Jan. 31 [cited 2024 Jul. 13];14(1):e2024023. Available from: https://dpcj.org/index.php/dpc/article/view/3506

Share